X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUVEN LIFE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUVEN LIFE DISHMAN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 25.1 17.5 143.1% View Chart
P/BV x 3.3 3.5 95.2% View Chart
Dividend Yield % 0.7 0.6 102.3%  

Financials

 DISHMAN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUVEN LIFE
Mar-18
DISHMAN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs374251 149.3%   
Low Rs129155 83.2%   
Sales per share (Unadj.) Rs197.849.1 402.6%  
Earnings per share (Unadj.) Rs21.29.7 218.2%  
Cash flow per share (Unadj.) Rs34.711.4 304.8%  
Dividends per share (Unadj.) Rs2.001.50 133.3%  
Dividend yield (eoy) %0.80.7 107.5%  
Book value per share (Unadj.) Rs179.960.3 298.4%  
Shares outstanding (eoy) m80.69127.28 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.1 30.8%   
Avg P/E ratio x11.920.9 56.8%  
P/CF ratio (eoy) x7.217.8 40.7%  
Price / Book Value ratio x1.43.4 41.6%  
Dividend payout %9.415.4 61.1%   
Avg Mkt Cap Rs m20,30625,825 78.6%   
No. of employees `0000.81.1 77.3%   
Total wages/salary Rs m5,355613 874.0%   
Avg. sales/employee Rs Th19,252.75,832.6 330.1%   
Avg. wages/employee Rs Th6,459.5571.5 1,130.2%   
Avg. net profit/employee Rs Th2,064.11,153.8 178.9%   
INCOME DATA
Net Sales Rs m15,9616,253 255.3%  
Other income Rs m265233 114.1%   
Total revenues Rs m16,2266,485 250.2%   
Gross profit Rs m4,1031,982 207.0%  
Depreciation Rs m1,091213 511.8%   
Interest Rs m94446 2,039.7%   
Profit before tax Rs m2,3341,955 119.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624718 86.8%   
Profit after tax Rs m1,7111,237 138.3%  
Gross profit margin %25.731.7 81.1%  
Effective tax rate %26.736.7 72.7%   
Net profit margin %10.719.8 54.2%  
BALANCE SHEET DATA
Current assets Rs m11,0185,622 196.0%   
Current liabilities Rs m9,5171,168 815.1%   
Net working cap to sales %9.471.2 13.2%  
Current ratio x1.24.8 24.0%  
Inventory Days Days11081 135.7%  
Debtors Days Days3536 97.0%  
Net fixed assets Rs m16,3043,325 490.4%   
Share capital Rs m161127 126.8%   
"Free" reserves Rs m12,9077,547 171.0%   
Net worth Rs m14,5167,674 189.1%   
Long term debt Rs m4,18914 30,139.6%   
Total assets Rs m29,8059,135 326.3%  
Interest coverage x3.543.2 8.0%   
Debt to equity ratio x0.30 15,934.3%  
Sales to assets ratio x0.50.7 78.2%   
Return on assets %8.914.0 63.4%  
Return on equity %11.816.1 73.1%  
Return on capital %17.526.0 67.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9525,066 97.7%   
Fx outflow Rs m6972,001 34.8%   
Net fx Rs m4,2553,065 138.8%   
CASH FLOW
From Operations Rs m2,786699 398.4%  
From Investments Rs m-1,529-6 25,063.9%  
From Financial Activity Rs m-941-577 163.1%  
Net Cashflow Rs m316116 272.1%  

Share Holding

Indian Promoters % 61.4 63.4 96.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.5 60.5%  
Shareholders   46,261 37,287 124.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS